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The Hedgehog (Hh) signal transduction pathway is critical to development, differentiation, growth, and cell migration. Although Hh signaling is significantly curtailed in adults, it retains functional roles in stem cell maintenance (Lai et al., 2003; Machold et al., 2003; van den Brink et al., 2004) and tissue repair (Ito et al., 1999; Miyaji et al., 2003; Karhadkar et al., 2004) . Aberrant Hh signaling pathway activation has been implicated as the cause of certain cancers, including basal cell carcinomas and medulloblastomas (Hahn et al., 1996; Dahmane et al., 1997; Reifenberger et al., 1998; Xie et al., 1998; Zurawel et al., 2000) , and in supporting the tumor microenvironment in numerous other cancers Watkins et al., 2003; Karhadkar et al., 2004; Dierks et al., 2007) via both Hh ligand-independent and ligand-dependent pathways. Smallmolecule antagonists of the Smoothened receptor (Smo) have entered human clinical trials for the treatment of advanced basal cell carcinoma and metastatic colorectal cancer (Von Hoff et al., 2008) Hh polypeptide secretion activates the Hh pathway through two membrane-associated receptors, Patched (Ptch) and Smo. Hh binds to Ptch, the 12-transmembrane spanning receptor, alleviating suppression of Smo, a seven-transmembrane protein that is structurally similar to G protein-coupled receptors. Smo activation stimulates the Gli family of transcription factors to induce the expression of specific genes, including Gli and Ptch, forming both a negative and a positive feedback loop.
Because of the important role the Hh pathway plays in tumorigenesis and stem cell maintenance, small-molecule regulators of the Hh pathway have attracted considerable interest as potential therapeutic agents. Cyclopamine, a plant-derived steroidal alkaloid, has been shown to directly bind to and inhibit the Smo receptor (Chen et al., 2002a) . Various screening efforts using cellular Hh pathway or biochemical assays directed at the Smo receptor have identified potent small-molecule agonists and antagonists with apparently competitive binding behavior for Smo (Chen et al., 2002b; Frank-Kamenetsky et al., 2002; Williams et al., 2003) . The 12-pass transmembrane protein Ptch is inhibitory to Smo. Under physiological conditions, activation of the pathway is caused by binding of the endogenous morphogen Hh to Ptch, which leads to internalization of Ptch and consequently alleviates the inhibitory affect of Ptch on Smo. The exact mechanism for Ptch inhibition of Smo has not been elucidated. In addition, no endogenous "orthosteric" agonist for Smo has been identified. In fact, it has been proposed that Ptch may translocate an endogenous sterol (such as cyclopamine), which inhibits activation and is relieved when Hh binds Ptch (Bijlsma et al., 2006 sor cell line and culture reagents Dulbecco's modified eagle's medium (DMEM)/GlutaMAX, Opti-MEM, newborn calf serum, nonessential amino acids, HEPES, and blasticidin were purchased from Invitrogen. Penicillin/streptomycin was purchased from Mediatech (Manassas, VA). Assay plates and compound dilution plates were purchased from Greiner Bio-One (Monroe, NC). Unlabeled cyclopamine and tomatidine were purchased from BIOMOL Research Laboratories (Plymouth Meeting, PA); 9-cyclohexyl-N-[4-(4-morpholinyl)phenyl]-2-(1-naphthalenyloxy)-9H-purin-6-amine (purmorphamine) and 3-keto-N-(aminoethyl-aminocaproyl-dihydrocinnamoyl)cyclopamine (cyclopamine-KAAD) were from Calbiochem (San Diego, CA); and SANT-1 was from Tocris (Ellisville, MO). SAG-1.3, SAG-1.5, SANT-2, Compound 1, -1H-benzimidazol-2-yl]phenyl}-2,3-dihydro-1,4-benzodioxin-6-carboxamide (ZЈЈЈЈ) were synthesized by the Medicinal Chemistry Research Department of GlaxoSmithKline Research Laboratories (Durham, NC) and WuXi Pharma (Shanghai, People's Republic of China). Phenylmethylsulfonyl fluoride, pepstatin, Complete EDTAfree protease tablets, and Triton X-100 were purchased from Roche Diagnostics (Indianapolis, IN). Leupeptin was purchased from Calbiochem (San Diego, CA). All other components of the membrane preparation buffers and all other standard reagents were purchased from Sigma-Aldrich (St. Louis, MO).
Generation of Recombinant BacMam Virus. The Smo BacMam virus was constructed and amplified based on published methods (Fornwald et al., 2007) . The coding region for the Smo gene, cloned in-house from human ovary, aligns with National Center for Biotechnology Information sequence NM_005631.3.
Transduction of HEK293F with Smo BacMam Virus. The cell line used for transductions, HEK293F, was purchased from Invitrogen. HEK293F cells were subcultured twice weekly in FreeStyle 293 expression medium (Invitrogen) and maintained in 3-liter sterile, plastic Erlenmeyer flasks on shaking platform set at 90 rpm in a humidified 37°C incubator with 5% CO 2 . Cells were seeded on day 0 at 6 ϫ 10 5 cells/ml. The next day, the transduction was performed at a cell density of 1.0 to 1.2 ϫ 10 6 cells/ml using 40 Smo BacMam virus particles per cell; the culture was supplemented with 2 mM sodium butyrate. Approximately 24 h later, transduced cells were harvested by centrifugation at 400g for 30 min at 4°C, washed once with a balanced salt solution, repelleted, and the pellet was flash-frozen in liquid nitrogen. The cell pellets were stored at Ϫ80°C until processed for membranes.
Membrane Preparation. HEK293F/Smo_BacMam cell pellets were resuspended at 4°C in 10 volumes of ice-cold buffer A (50 mM HEPES, pH 7.4, 1 mM EDTA, 25 g/ml bacitracin, and 100 M leupeptin) plus 1 mM phenylmethylsulfonyl fluoride and 2 M pepstatin per gram of cell pellet, homogenized in a Waring Blender for 15 s, placed on ice for 5 min, and homogenized for an additional 15 s. To remove large particles, a low-speed centrifugation (500g for 30 min at 4°C) was performed, followed by high-speed centrifugation (48,000g for 45 min at 4°C), resuspension in buffer A plus 2 M pepstatin, and a final high-speed centrifugation (48,000g for 45 min at 4°C). A Dounce homogenizer was used to resuspend the final pellet using ice-cold buffer A. The membrane suspension was passed through a 23-gauge needle, aliquoted, and stored at Ϫ80°C. Total protein concentration of the membrane preparation was determined with a Coomassie Plus reagent kit from Pierce Chemical (Rockford, IL) using bovine serum albumin as the standard.
[ 3 H]SAG-1.3 and [ 3 H]Cyclopamine Radioligand Binding Assays. Radioligand binding assays were performed under the same conditions, independently of the radioligand used. Membranes were diluted in buffer B (50 mM HEPES and 3 mM MgCl 2 , pH 7.2, at 23°C) to a concentration of 0.01 to 0.02 mg protein/ml. Assays were initiated by the addition of 200 l of membrane suspension to 100 l of radioligand at 1 to 3 times radioligand K d and various concentrations of inhibitors in buffer B plus a cocktail of protease inhibitors (EDTA-free; Roche Diagnostics) and 0.02% bovine serum albumin to reduce nonspecific binding. Binding assays were performed in dupli-cate in polypropylene 96-well plates (Costar; Corning Life Sciences, Acton, MA). Nonspecific binding was defined in the presence of 1 to 10 M cyclopamine ([ 3 H]SAG-1.3 assays) or 10 M SANT-2 ([ 3 H]cyclopamine assays). Competition assays were performed at 23°C for 5 h to allow adequate time for the two ligands to reach equilibrium for binding. The separation of bound from free radioligand was accomplished by rapid vacuum filtration of the incubation mixture over glass fiber filters (Inotech Biosystems, Rockville, MD) presoaked for 2 h in 0.3% polyethylenimine, pH 13.0, using a cell harvester (Inotech Biosystems). Filters were washed 2 times with 0.3 ml of ice-cold phosphate-buffered saline, pH 7.0, containing 0.01% Triton X-100. Radioactivity on the filters was quantified using a TopCount liquid scintillation counter (PerkinElmer Life and Analytical Sciences, Boston, MA). Radioactive saturation experiments were performed with the addition of labeled [
3 H]SAG-1.3 over a range of concentrations (0.1-100 nM). Isotopic unlabeled saturation studies were carried out using [ 3 H]cyclopamine or [ 3 H]SAG-1.3 at two fixed concentrations in the presence of varied concentrations of unlabeled cyclopamine (0.001-10 M) or SAG-1.3, respectively. Mode of inhibition (MOI) studies were performed using similar conditions including double titrations of both radioligand and unlabeled Smo ligands.
BODIPY-Cyclopamine Whole Cell Binding Assay. HEK MS RII cells were transduced at a density of 3 ϫ 10 5 cells/ml with 17 Smo BacMam virus particles/cell in DMEM containing 0.5% fetal bovine serum and seeded at 15,000 cells/well in 384-well poly-D-lysinecoated plates followed by overnight (Ͼ20-h) incubation at 37°C and 5% CO 2 . Compound stocks were prepared in dimethyl sulfoxide, except for BODIPY-cyclopamine, which was prepared in 100% ethanol, according to the manufacturer's instructions. On day 2, DMEM media were removed with a Power Washer 384 (Tecan, Durham, NC); cells were fixed by adding 3.7% (v/v) formaldehyde (VWR, Bridgeport, NJ) to the plates using a Multidrop 384 (Thermo Fisher Scientific, Waltham, MA) and incubated for 20 min. After aspirating, the fixation buffer, 2 M SYTO-63, 25 nM BODIPY-cyclopamine, and indicated concentrations of compounds (all diluted in Hanks' balanced salt solution without Ca 2ϩ /Mg 2ϩ ; Invitrogen) were transferred to the assay plates with a Cybi-well (Cybio, Jena, Germany). Assay plates were incubated for 2 h, washed several times with buffer, and then imaged on an Opera instrument (PerkinElmer Life and Analytical Sciences). The fixing and washing protocol was optimized to eliminate nonspecific binding of the BODIPY-cyclopamine probe. On the Opera instrument, 635-nm and 488-nm excitation lasers were used to excite SYTO-63 and BODIPY, respectively, whereas 690/50-and 525/50-nm filters were used to collect the fluorescence signals. A primary 405/488/635-nm dichroic filter was used to filter laser light; a 650-nm long pass filter was used to split SYTO-63 and BODIPY emission wavelengths, sending wavelengths longer than 650-nm to the 690/50-nm filter and the remaining light to the 568-nm dichroic filter. The 568-nm dichroic filter was used to send wavelengths shorter than 568 nm to the 525/50-nm filter for detection of the BODIPY signal. Laser power and exposure times were optimized to avoid any cross talk between detection channels. The SYTO-63 signal was used to identify all cells as objects, whereas the BODIPY signal was used to quantify BODIPY-cyclopamine binding to Smo receptors in cells. Acapella software in the Opera imaging system was used to develop the analysis algorithms for quantification of the images.
␤-Lactamase Reporter Gene Assay. CellSensor Gli-␤-lactamase NIH3T3 cells were maintained at 20 to 80% confluence in DMEM/GlutaMAX media supplemented with 10% newborn calf serum, 0.1 mM nonessential amino acids, 25 mM HEPES, pH 7.3, 100 U/ml penicillin, 100 g/ml streptomycin, and 5 g/ml blasticidin. Assay medium was Opti-MEM supplemented with 0.5% newborn calf serum, 0.1 mM nonessential amino acids, 1 mM sodium pyruvate, 10 mM HEPES, 100 U/ml penicillin, and 100 g/ml streptomycin. Antagonist and agonist assays were carried out in black-wall, clear-bottomed, 384-well assay plates with 10,000 cells/well. For the antagonist assay, cells were plated using a Multidrop 384 (Thermo Fisher Scientific) at a volume of 20 l/well in the presence of an agonist (EC 80 ), followed by the addition of test compounds with a Cybi-well, and incubated for 40 to 48 h before detection. For the agonist assay, cells were plated, compounds were added as described above, and plates were incubated in the presence of test compounds for 40 to 48 h before detection. Final assay conditions included 1% dimethyl sulfoxide final concentration in a 25-l total volume assay. After the 40-to 48-h incubation, 5 l of a 6ϫ LiveBlazer loading reagent (prepared as instructed by Invitrogen) was added to the assay plates using a Multidrop 384. Plates were then read using an Envision reader (PerkinElmer Life and Analytical Sciences) in bottom-read mode, with an excitation wavelength of 409 nm and emission wavelengths of 460 and 535 nm to measure the ratio of fluorescence intensity at 460 versus 535 nm as specified by Invitrogen.
Data Analysis. The binding rate constants (k ϩ1 and k Ϫ1 ), apparent equilibrium dissociation constants (K d ), and the maximum number of binding sites (B max ), EC 50 , IC 50 , and K i analysis were performed using the nonlinear iterative curve-fitting computer program GraphPad Prism (GraphPad Software Inc., San Diego, CA). MOI analysis was performed using GraphPad Prism as described under Results.
Results

Characterization of [ 3 H]SAG-1.3 Binding to HEK293 FSmo Cell Membranes. Binding of [
3 H]SAG-1.3 (2-4 nM) was observed at 23°C to membranes derived from HEK293FSmo cells and not to those from the HEK293F cells transfected with the vector control (Supplemental Fig. 1 ). Incubation of various amounts of HEK293FSmo-derived membrane homogenates with [
3 H]SAG-1.3 indicated that binding of the radioligand was linear with protein concentrations up to 12 g/well (Supplemental Fig. 2 ). Based on the protein titration, a final membrane protein concentration of 2 to 4 g/well was used in subsequent assays. Specific binding measured at this protein concentration was between 1 and 10% of the total amount of radioligand added, indicating that radioligand depletion was insignificant because of the low receptor concentration used (i.e., total [L] ϳ free ligand). Nonspecific binding was defined in the presence of 1 M SAG-1.3 as well as 1 to 10 M cyclopamine or cyclopamine-KAAD. Both yielded a common plateau of maximal inhibition. Cyclopamine was chosen for subsequent studies because it is structurally distinct from (Fig. 1, A and B (Fig. 2A) . Affinity and B max values derived from orthogonal homologous isotopic unlabeled saturation experiments yielded K d ϭ 5.9 Ϯ 1.7 nM and B max ϭ 40 Ϯ 8 pmol/mg protein (Fig. 2B) . The limit of detection for competing compounds using this radioligand was calculated from the density of receptors (B max ) expressed in the membrane preparation. Based on the B max determined from saturation binding assays as well as the affinity of [
3 H]SAG-1.3, the limit of compound affinity that could be measured using this radioligand was 0.26 to 1.5 nM depending on the final assay volume (1-0.15 ml).
Homologous Fig. 3 . Iterative nonlinear analysis indicated a single binding site (Hill values of 0.9 -1.1; K d ϭ 10 Ϯ 2.5 nM; B max ϭ 20 Ϯ 0.9 pmol/mg protein). Based on the density of receptors determined from saturation binding assays, as well as the affinity of [ 3 H]cyclopamine, the limit of compound affinity that could be measured using this antagonist radioligand was 0.4 to 2.6 nM, depending on the final assay volume (1-0.15 ml). The SAG-1.3 and SAG-1.5 agonists are structurally related, whereas the purmorphamine agonist is structurally distinct. Likewise, the cyclopamine, cyclopamine-KAAD, and tomatadine (inactive) antagonists are structurally similar, whereas SANT-1, SANT-2, ZЈЈЈЈ, Compound 1 (a Smo antagonist that is the racemate of a representative example #8 structure from Novartis (Basel, Switzerland) , and GDC-0449, Genentech's (South San Francisco, CA) clinical Smo antagonist (Von Hoff et al., 2008) (Fig. 4) , represent distinct chemotypes. SAG-1.5 was the most potent agonist inhibitor of [ 3 H]SAG-1.3 binding to Smo (K i ϭ 0.5 nM). SAG-1.3 bound with high affinity (K i ϭ 1 nM) followed by the antagonists GDC-0449, ZЈЈЈЈ (Compound 1), cyclopamine-KAAD, SANT-2, and cyclopamine (Fig. 5, A and B, and summarized in Table 3 ). It is noteworthy that GDC-0449 inhibited the binding of [ 3 H]SAG-1.3 in a biphasic manner, with an apparent high affinity of 1.3 nM and low affinity of 2.3 M (Fig. 5B ). Purmorphamine and tomatidine (an inactive analog of cyclopamine) were weak inhibitors of binding (inactive up to 10 M). SANT-1 only exhibited partial inhibition (40%) of [
3 H]SAG-1.3 binding, with a plateau from 0.04 to 10 M, suggesting a possible allosteric interaction between SANT-1 and SAG-1.3.
Because of the differential response the agonists and antagonists exhibited against small-molecule agonist [
3 H]SAG-1.3 binding, we performed competition experiments with the same set of compounds using [ 3 H]cyclopamine (an antagonist) as the radioligand (Table 3) . GDC-0449 possessed the highest affinity for smoothened receptors labeled by [ Table 3 ). Purmorphamine lacked significant inhibition up to the highest concentration tested. The binding profiles of cyclopamine, cyclopamine-KAAD, and the inactive analog tomatidine using [ 3 H]cyclopamine were consistent with affinities measured using the agonist radioligand. The antagonist molecules ZЈЈЈЈ, SANT-1, and SANT-2 showed high affinities for Smo labeled by [ 3 H]cyclopamine ( Fig. 5D ; Table 3 ). In contrast to the partial inhibition of Mode of Inhibition Studies. The finding that SANT-1 only partially inhibited [
3 H]SAG-1.3 binding to Smo in competition assays suggests that various ligands may bind to Smo at distinct sites. To further investigate the MOI of these ligands, double titrations of both radioligand and compounds were performed for SAG-1.5, cyclopamine, SANT-1, and SANT-2. Compound displacement (specific binding) and apparent IC 50 values were examined in the presence of varying concentrations of the radioligand probe. This radioligand binding method is comparable with Schild plot analysis (Ehlert and Authors, 1988) and is often referred to as Schild-type plots (Schetz and Sibley, 1997) . Competitive binding interactions show a linear shift in apparent IC 50 in relation to radioligand concentration, whereas allosteric antagonism can result in an incomplete inhibition of specific binding and or a nonlinear hyperbolic plot of IC 50 values. In addition, the data can be quantified by fitting to a modified model based on the Cheng-Prusoff equation (Kenakin, 2006) : (Fig. 6, A and B) . Cyclopamine also behaved in a competitive manner, with ␣ Ͼ100 in three experiments (Fig. 6, C (Fig. 7, A and B) . In addition, the data were fit to a more complex ternary model (Kenakin, 2006) to further quantify the interactions (data not shown). This analysis yielded affinity and ␣ values that were consistent with the previous determinations, indicating a probedependent allosteric interaction for SANT-1 and SANT-2 for [ 3 H]SAG-1.3 binding to Smo.
Whole Cell BODIPY-Cyclopamine Binding Assay. The potencies of known smoothened ligands and analogs for inhibition of fluorescent BODIPY-cyclopamine binding to smoothened receptors are summarized in Table 3 . The rank order and potency of the compounds tested in the BODIPYcyclopamine assay were similar to the affinities determined in both the ␤-Lactamase Reporter Gene Functional Assay. To understand the functional consequence of partial competition of [ 3 H]SAG-1.3 by antagonists such as SANT-1 and 2, we also tested these agonists and antagonists in a ␤-lactamase reporter gene functional assay (Table 3 ). The purine derivative agonist purmorphamine exhibited weak activation of the system, consistent with previous observations in similar mouse reporter systems (Sinha and Chen, 2006) . Both SAG-1.3 and SAG-1.5 displayed nanomolar-range potency stimulation of Gli-responsive reporter activity, with EC 50 values of 0.4 and 7 nM, respectively. Because SAG-1.5 was competitive with [ 3 H]SAG-1.3 for binding to Smo, yet was superior in potency than the structurally similar SAG 1.3 in ␤-lactamase reporter gene functional assay, an EC 80 concentration of SAG 1.5 was used as the reporter activator for evaluation of functional inhibitors of Smo. The antagonist ligands SANT-1 and GDC-0449 were the most potent, with IC 50 values of 20 and 45 nM, respectively. Additional antagonist ligands, such as cyclopamine-KAAD, SANT-2, ZЈЈЈЈ, and Compound 1, retained similar rank order pharmacological potencies to the measured binding affinities determined using both agonist and antagonist radioligands. All of these antagonists, including SANT-1 and -2, exhibited complete inhibition of the response to the level of background (Fig. 8) .
Discussion
The Hh pathway plays an important role in development, stem cell maintenance, and tumorigenesis. The pathway activator Smo is being pursued as an attractive target for cancer, and small-molecule antagonists of Smo have entered clinical trials for the treatment of multiple cancers, including advanced basal cell carcinoma and metastatic colorectal cancer. A better understanding of the interactions and regulations of antagonists and agonists of Smo will facilitate the design and discovery of the next generation of small-molecule regulators of Smo and the Hh pathway.
The radioligand binding of a Smo agonist, [ 3 H]SAG-1.5, has been characterized previously (Frank-Kamenetsky et al., 2002) . We have extended their study by examining the binding of both an agonist, ϭ 36 min) . Because of this, we performed mathematical analysis to show that when the radioligand dissociates more slowly than a competing ligand, binding is close to equilibrium conditions at t ϭ 3.5/k Ϫ1 for the radioligand. In the absence of definitive rate constants for the competing ligands tested, we allowed the binding to equilibrate for 5 to 7 h, with no apparent detriment to membrane or ligand integrity. Binding of [ 3 H]cyclopamine to smoothened receptors displayed a biphasic association ( Fig. 1 to a single site with high affinity, yielding K d values of 1.7 Ϯ 0.6 and 10 Ϯ 2.5 nM, respectively (Fig. 2) , 2002) . The affinities for most of the other compounds examined were in agreement with previously reported functional potencies, with the exception of purmorphamine, a hedgehog pathway activator. Purmorphamine has been reported to inhibit BODIPY-cyclopamine binding to Smo (IC 50 of ϳ1 M) and purmorphamine-driven activation of Gli-dependent reporter was inhibited by cyclopamine (Sinha and Chen, 2006 Tables 1 and 2. ertheless produce full functional inhibition. Site-directed mutagenesis studies using both binding and functional assays would supplement these data and enhance the understanding of smoothened receptor agonist and antagonist mechanism of action. Our results support the general bias observed in binding assays compared with functional assays. Because of this, we re-emphasize that the choice of ligand used in radio-or fluorescent binding studies should be considered, because each probe might specifically identify different sets of allosteric and competing compounds. The subtle differences in binding of allosteric ligands such as SANT-1 and SANT-2 may result in unique phenotypes because they may change the way smoothened receptors interact with accessory proteins. In addition, the specific cellular phenotype can influence the action of such ligands and is worthy of further investigation.
In conclusion, we have characterized radioligand binding of both an agonist and an antagonist of Smo. Using both probes, we have compared the binding of multiple antagonists and agonists to Smo. Our detailed biochemical mechanism of action analyses indicate SANT-1 and SANT-2 are allosteric inhibitors of [ 3 H]SAG-1.3 binding. Our data have important implications on the understanding of Smo regulation and discovery of additional small-molecule Smo regulators. Fig. 8 . Inhibition by SANT-1 and SANT-2 of the SAG-1.5 induced ␤-lactamase response. CellSensor NIH3T3 cells stably expressing the Gli-␤-lactamase reporter were exposed to compounds for 40 to 48 h in the presence of an EC 80 concentration of SAG-1.5. Zero percent and 100% correspond to the basal level of fluorescence and to the SAG-1.5 induced fluorescence level, respectively. Data are representative of more than three separate experiments all performed in two to six replicates.
